Fri, Aug 1, 2014, 1:04 AM EDT - U.S. Markets open in 8 hrs 26 mins


% | $
Click the to save as a favorite.

Prana Biotechnology Limited Message Board

  • mtaotter mtaotter Sep 23, 2013 9:08 AM Flag

    While we wait....

    In rereading through PRANA'S website, I came across their 2011 position statement.

    It is located under "R&D Activities"
    Then select the bottom tab: "Therapeutic Strategy Statement"

    As I work (with other posters) toward a third draft to understand PBT2, I read this statement with far more attention.

    I think it will warm some cold feet as we await further results and updates.


    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Another one?
      In the present study, Craddock and his team made three major discoveries. They discovered that specific zinc-tubulin binding sites promote side-to-side tubulin interactions, which are vital to MT polymer structure and demonstrated the method in which extra-neuronal zinc sequestration decreases intra-neuronal zinc available to tubulin, hence destabilizing MTs and leading to tangles by performing a kinetic analysis.

      They also demonstrated that metallomic imaging mass spectrometry (MIMS) of AD model mice revealed abnormal zinc distribution in critical brain regions.

      The findings indicate that therapies based on stabilizing MTs could normalize intra-neuronal zinc levels by administering zinc ionophore drugs like PBT2 (Prana Biotechnology) and promote MT self-assembly and stability by other drugs and through transcranial therapies, for instance through ultrasound at MT resonant frequencies in megahertz.

      Tanzi, who is a leading Alzheimer's expert concluded:

      "It looks like beta-amyloid plaques themselves aren't destructive directly, but lead to lower zinc levels within neurons. This in turn disrupts microtubules and tau, causing tangles and memory loss. Protecting microtubules and their association with tau may be the best treatment approach in Alzheimer's disease."

    • Can you use this?
      In 2007, Dr. Steven Hersch and colleagues showed that concentrations of copper are
      elevated in HD and provided evidence that interactions between copper and the HD
      protein and highly copper-sensitive lactate dehydogenase (LDH) contribute to HD

    • A Good Read!!

    • Just one bump for those who missed it.

      • 1 Reply to mtaotter
      • mtaotter, with the BACE inhibititors now being spruiked as the latest good thing, there is a passage in that statement that may be a preview to their results. Flurizan did selectively reduce AB42 in isolation and got nothing on cognition. I don't want the BACE inhibitors to fail, it is just I think they will. I am surprised they didn't go right to prodromal where they would have a better chance. Flurizan was scrapped.

        Sentiment: Strong Buy

2.19-0.07(-3.10%)Jul 31 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.